Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 4Pulmonary Disease, Chronic Obstructive 1Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Standard of Care 3Educational Status 2vilanterol 1tocilizumab 1perflutren 1X-Rays 1Tiotropium Bromide 1Therapeutics 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Sulfur Hexafluoride 1Specimen Handling 1Singing 1Salmeterol Xinafoate 1Rehabilitation 1Pulmonary Surgical Procedures 1Prednisolone 1Practice Guidelines as Topic 1Pharmacists 1Methods 1Massage 1Magnesium Sulfate 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Iloprost 1Hypnosis 1Hematologic Tests 1Geritol 1General Practitioners 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pulmonary Disease, Chronic Obstructive × Iloprost × Clear all
NCT05411107 2024-05-17

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡